Vaccines and therapeutics to speculate growth during the affected season: Ken Research REQUEST FOR SAMPLE REPORT Request For sample Report × Report Title Name Email Designation Phone No Comapny Name Comapny URL Country -- Please Select Your Country -- Afganistan Africa Albania Algeria Andorra Angola Anguilla Antigua and Barbuda Argentina Armenia Aruba Asia Australasia Australia Austria Azerbaijan Bahamas Bahrain Bangladesh Barbados Belarus Belgium Belize Benin Bermuda Bhutan Bolivia Bonaire Bosnia Herzegovina Botswana Brazil BRICS British Virgin Islands Brunei Darussalam Bulgaria Burkina Faso Cambodia Cameroon Canada Cape Verde Cayman Islands Central African Republic Central and South America Chad Chile China Colombia Comoros Congo Costa Rica Cote d'Ivoire Croatia Cuba Curacao Cyprus Czech Republic Denmark Djibouti Dominica Dominican Republic Ecuador Egypt El Salvador Equatorial Guinea Eritrea Estonia Ethiopia Europe European Union Falkland Islands Faroe Islands Fiji Finland France French Guiana French Polynesia Gabon Gambia Georgia Germany Ghana Gibraltar Global Great Britain Greece Greenland Grenada Guadeloupe Guam Guatemala Guerney & Alderney Guinea Guinea-Bissau Guyana Haiti Honduras Hong Kong Hungary Iceland India Indonesia Iran Iraq Ireland Isle of Man Israel Italy Ivory Coast Jamaica Japan Jersey Jordan Kazakhstan Kenya Kiribati Kosovo Kuwait Kyrgyzstan Laos Latvia Lebanon Lesotho Liberia Libyan Arab Jamahiriya Liechtenstein Lithuania Luxembourg Macao Macau Macedonia Madagascar Malawi Malaysia Maldives Mali Malta Man (Island of) Marshall Islands Martinique Mauritania Mauritius Mayotte Mexico Micronesia Middle East Minnesota Moldova Monaco Mongolia Monserrat Montenegro Morocco Morroco Mozambique Myanmar Namibia Nepal Netherlands New Caledonia New Zealand Nicaragua Niger Nigeria Niue North America North Korea Norway Oman Pakistan Palau Palestine Panama Papua New Guinea Paraguay Peru Philippines Poland Portugal Puerto Rico Qatar Reunion Romania Russia Rwanda Saint Helena Saint Lucia Saint Martin Saint Pierre and Miquelon Saint Vincent and the Grenadines Samoa Samoa (American) San Marino Sao Tome and Principe Saudi Arabia Scandinavia Senegal Serbia Seychelles Sierra Leone Singapore Sint Maarten Slovakia Slovenia Solomon (Islands) Somalia South Africa South Korea South Sudan Spain Sri Lanka Sudan Suriname Svalbard and Jan Mayen Islands Swaziland Sweden Switzerland Syria Taiwan Tajikistan Tanzania Thailand Timor Leste Togo Tonga Trinidad and Tobago Tunisia Turkey Turkmenistan Turks and Caicos Islands Uganda Ukraine United Arab Emirates United Kingdom United States Uruguay Uzbekistan Vanuatu Vatican City Venezuela Vietnam Virgin Islands Western Sahara Yemen Zambia Zimbabwe Requirement Submit Influenza virus in the US affects the costs of medical care, loss of work productivity, and deaths which are the outstanding impacts on the socio-economic factors during the season. The socio-economic factors are very essential for influenza control and therefore, the population affected by the virus need to be prepared for their health interventions. It was estimated that the influenza virus medical costs accounts for approximately 3 billion dollars. On an average of over two hundred thousand people are hospitalized every year and 23,000 of the population die due to respiratory and circulatory complications accompanied with seasonal influenza virus infections. Statistical regression models were used to observe the influenza virus impact in the United States. Majority of the population in the United States do not consider the virus as alarming and also do not believing that the vaccine works. In the US consumers consider a basket of goods as very essential in the flu season. Women find more products essential than men during flu season such as cough, cold medications, facial tissues and hand sanitisers, and others products to maintaining their health and control their symptoms. More women consider such products more essential than men. The severity of the influenza virus is estimated by the availability and utilisation of the influenza vaccine, and the type of vaccine available. Every spring, the World Health Organization (WHO) collects influenza virus samples from around the world and develops the upcoming season’s vaccine. Inactivated influenza vaccines (IIV) and live attenuated vaccines (LAIV) are the two types of vaccine available in the United States. According to the study “Disease Snapshot: Consumer Impact of Seasonal Influenza in the US”, the sales of cough, cold and allergy products (CCAs) are very high when the government provided influenza vaccine is less effective. Vitamins and dietary supplements are the other products used during the flu season for prevention along with the combination CCAs and nasal sprays for fevers and coughs, and tissue products for nasal congestion. Allergy Care, Herbal/Traditional Products, OTC, Paediatric Consumer Health, Sports Nutrition, Weight Management and Wellbeing are few of the necessary products for the population affected with the influenza virus. The increased technological advancements in medical diagnostics is an indication of technology based, cost-effective devices in the diagnostic industry. Majority of the manufacturers are focusing on developing new-generation POC influenza tests such as LoC/microchip technology based on micro-electromechanical system (MEMS) that adapts biological and chemical applications. However, sophisticated influenza virus tests are available only in specialized laboratories across the globe. To measure the efficacy and acceptability of a product for a consumer for any diagnostic tests, it is highly recommended to analysing the product safety features. This is to ensure that the product is suitable for the consumers with international standards. The leading regulatory organizations that deal with the product safety are Alere, BD, Quidel, bioMrieux, CorisBioconcept, Meridian Bioscience, Response Biomedical (acquired by OrbiMed), Princeton BioMeditech Corporation, SA Scientific, Sekisui Diagnostics, and Thermo Fisher Scientific. These organizations give clearance to the manufacturers to display specific mark that is accepted in particular countries. The influenza virus vaccinations are manufactured in hundreds of million doses within a very short time period to meet the needs of the affected population in the US. An emergence innovative production of a vaccine system based on mammalian or insect cell cultures has answered many questions and hurdles associated with the egg-based production system. Such industrially well-established production systems provide more flexible and quick response to pandemic threats such as influenza virus. It was analysed that there is a need for developing alternative vaccine production systems based on plants, bacteria, yeast and cell cultures. The influenza virus vaccines account for about 80% of the market while the remaining are for therapeutics which is the fastest growing market aforementioned flu virus analysis period. It was estimated that the influenza virus therapeutics market will witness a positive growth during the affected season. Source: https://www.kenresearch.com/healthcare/general-healthcare/disease-snapshot-consumer-impact-of-seasonal-influenza-us/139313-91.html Related Reports Seasonal Influenza Vaccines-Current and Future Players Seasonal Influenza Vaccines-US Drug Forecast and Market Analysis to 2025 Contact Us: Ken Research Ankur Gupta, Head Marketing & Communications sales@kenresearch.com 0124-4230204 Post Views: 4 Tags: Global influenza vaccine Market, Influenza vaccine market product development, North America influenza vaccine market research, Pediatric influenza Vaccine demand in US, Pediatric Vaccine demand in US, Suppliers of influenza vaccine in US, US adult vaccine market analysis, US disease prevalence rate, US flu vaccine manufacturers, US influenza vaccine industry analysis, US influenza vaccine market revenue, US seasonal influenza vaccine market, US vaccine market regulations, US Vaccine market research, US vaccine therapeutics market